Skip to content
Shukra Pharmaceuticals logo

Shukra Pharmaceuticals

SHUKRAPHAR NSE
₹79.87 +0.02 (+0.03%)
P/E
98.60
View as Markdown
MCP
Close 4 Nov 2026 ₹79.87 +39.70 +98.8% 1Y
Start ₹40.17

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
37.00%
Debt to Equity
0.06
EPS (TTM)
₹0.81
Book Value
₹2.28
Market Cap
—
P/E (TTM)
98.60
P/B
35.03
ROE
28.90%
Dividend Yield
0.01%
EBITDA
₹33.30 Cr
52W High
₹84.20
52W Low
₹26.30
Day Range
₹79.78 – ₹82.30
Volume
45,04,073

Peer Comparison

Healthcare › Pharmaceuticals

Shukra Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Shukra Pharmaceuticals (this company)
₹79.8798.60₹3,551 Cr35.030.01%28.90%37.00%₹75 Cr₹35 Cr
Median 8 companies₹1,587.7058.71₹1,25,337 Cr7.290.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

61 Good

Data confidence 100/100

Category scores

Quality
59
Good
Returns, margins, earnings quality 22% weight
Valuation
16
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
89
Strong
Solvency, leverage, coverage 9% weight
Momentum
99
Strong
Trend strength, vol-adjusted 12% weight
Ownership
72
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 175% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%

Weaknesses

2
  • Stock is trading at 34.4 times its book value
  • Debtor days have increased from 122 to 148 days.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish4213
OscillatorsBearish423
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
75.70
Bearish
MACD (12,26,9)
5.12
Bullish
SMA (50)
60.46
Bullish
SMA (200)
41.82
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+27.55%
5Y+38.96%
3Y−1.14%
1Y+72.73%
TTM+114.29%

Net profit

Net profit growth by window
10YZero base
5YZero base
3Y+76.52%
1Y+120.00%
TTM+250.00%

Operating cash flow

Operating cash flow growth by window
10Y0.00%
5Y+24.57%
3Y0.00%
1Y−62.50%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+30.88 pp
5Y+41.79 pp
3Y+42.41 pp
1Y+11.49 pp
TTM+28.19 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹5.00 Cr
Mar 2018₹5.00 Cr
Mar 2019₹6.00 Cr
Mar 2020₹12.00 Cr
Mar 2021₹11.00 Cr
Mar 2022₹20.00 Cr
Mar 2023₹59.00 Cr
Mar 2024₹75.00 Cr
Mar 2025₹33.00 Cr
Mar 2026₹57.00 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹1.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹1.00 Cr
Mar 2023₹4.00 Cr
Mar 2024₹19.00 Cr
Mar 2025₹10.00 Cr
Mar 2026₹22.00 Cr

Quarterly Results

₹ Cr
524632 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
20
25
19
11
3
6
11
13
5
6
39
6
24
Expenses
20
20
9
6
2
5
7
6
4
6
12
6
2
Operating Profit
0
5
10
4
1
1
4
7
1
0
27
1
21
OPM %
1.7%
21%
51%
41%
25%
12%
37%
55%
24%
−7%
69%
11%
90%
Other Income
1
0
1
1
1
1
1
1
1
2
1
1
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
1
1
1
1
1
1
1
1
1
1
1
1
PBT
0
5
10
5
1
1
4
8
1
0
27
0
20
Tax %
2%
0%
1%
24%
41%
39%
23%
29%
26%
−1090%
24%
568%
26%
Net Profit
0
5
9
4
0
1
3
5
1
2
20
−2
15
EPS (₹)
0.01
0.11
0.22
0.09
0.01
0.01
0.07
0.12
0.02
0.05
0.46
−0.04
0.34

Profit & Loss

₹ Cr
524632 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3
5
5
5
6
12
11
20
59
75
33
57
75
Expenses
3
4
4
4
4
10
10
18
53
55
20
28
26
Operating Profit
0
1
1
2
2
2
1
3
5
19
13
29
49
OPM %
−10%
24%
28%
30%
29%
13%
13%
14%
9%
26%
39%
51%
65%
Other Income
1
0
0
0
0
0
0
0
1
3
4
5
4
Interest
0
0
0
0
0
0
0
0
0
0
1
1
1
Depreciation
1
0
0
1
1
1
1
2
2
2
3
3
4
PBT
0
0
1
1
1
0
0
1
4
20
13
29
48
Tax %
52%
66%
52%
45%
37%
82%
−90%
26%
1%
7%
28%
23%
—
Net Profit
0
0
0
1
0
0
0
1
4
19
10
22
36
EPS (₹)
0
0
0.01
0.01
0.01
0
0
0.02
0.1
0.42
0.22
0.5
0.81
Div. Payout %
0%
0%
16%
15%
17%
0%
0%
10%
4%
6%
5%
2%
—

Balance Sheet

₹ Cr
524632 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
2
2
2
2
2
2
4
11
44
44
Reserves
12
13
13
13
14
14
14
15
21
47
19
46
Borrowings
1
0
0
4
6
8
10
3
5
3
4
5
Other Liabilities
3
3
4
6
7
10
10
15
45
17
20
23
Total Liabilities
18
17
19
24
28
34
36
35
75
78
87
117
Fixed Assets
10
10
10
14
16
17
18
18
20
20
19
22
CWIP
2
2
2
2
2
2
2
2
2
2
2
12
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
7
6
7
8
11
14
16
16
53
56
65
84
Total Assets
18
17
19
24
28
34
36
35
75
78
87
117

Cash Flow

₹ Cr
524632 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−2
3
0
1
0
1
1
8
3
−5
8
3
Investing
1
0
−1
−5
−2
−3
−2
−2
−4
−1
−1
−14
Financing
1
−1
0
3
2
2
2
−7
5
12
−5
5
Net Cash Flow
0
1
−1
0
0
0
0
0
4
6
2
−6
Free Cash Flow
−1
2
−1
−4
−2
−2
−1
6
−1
−7
5
−13
CFO/OP
812
237
7
63
25
81
38
292
64
−24
92
17

Ratios

524632 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
73
71
175
200
345
245
318
132
187
120
98
148
Inventory Days
554
92
112
53
100
169
221
139
25
19
447
320
Days Payable
291
108
400
734
1,161
786
702
303
271
59
414
232
Cash Conversion Cycle
335
54
−112
−480
−717
−372
−163
−32
−58
80
131
236
Working Capital Days
758
258
344
379
440
226
278
57
41
157
403
352
ROCE %
−1%
6%
7%
6%
4%
0%
1%
6%
19%
44%
22%
37%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Shukra Pharmaceuticals insights

60 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 51.15%
  • Others 38.55%
  • Public 9.65%
  • FIIs 0.44%
  • DIIs 0.22%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Shukra Pharmaceuticals

What does Shukra Pharmaceuticals Ltd do?
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing
Where is Shukra Pharmaceuticals Ltd (SHUKRAPHAR) listed?
Shukra Pharmaceuticals Ltd trades as SHUKRAPHAR on the NSE and under code 524632 on the BSE.
Which sector does Shukra Pharmaceuticals Ltd belong to?
Shukra Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd trades at a PE ratio of 98.60 as of 4 Nov 2026, on earnings per share of ₹0.81, against a book value of ₹2.28 per share.
What is the 52-week high and low of Shukra Pharmaceuticals Ltd?
Over the last 52 weeks Shukra Pharmaceuticals Ltd has traded between ₹26.3 and ₹84.2 as of 4 Nov 2026.
Does Shukra Pharmaceuticals Ltd pay dividends?
Shukra Pharmaceuticals Ltd has a dividend yield of 0.01%.
What is the Return on Equity (ROE) of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd reported a return on equity of 28.90%. Its debt-to-equity ratio is 0.06.

Company Information

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing

Website shukrapharmaceuticals.com
CEO Mr. Dakshesh Rameshchandra Shah
Employees 115
Listed 14 Aug 2026
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524632.md for Shukra Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month